- Home
- MAIA vs CUE Comparison
MAIA vs CUE Comparison
Compare MAIA & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- CUE
- Stock Information
- Founded
- MAIA 2018
- CUE 2014
- Country
- MAIA United States
- CUE United States
- Employees
- MAIA N/A
- CUE N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- CUE Health Care
- Exchange
- MAIA Nasdaq
- CUE Nasdaq
- Market Cap
- MAIA 46.7M
- CUE 48.0M
- IPO Year
- MAIA 2022
- CUE 2018
- Fundamental
- Price
- MAIA $1.73
- CUE $0.78
- Analyst Decision
- MAIA
- CUE Strong Buy
- Analyst Count
- MAIA 0
- CUE 3
- Target Price
- MAIA N/A
- CUE $3.00
- AVG Volume (30 Days)
- MAIA 416.1K
- CUE 267.4K
- Earning Date
- MAIA 08-08-2025
- CUE 08-13-2025
- Dividend Yield
- MAIA N/A
- CUE N/A
- EPS Growth
- MAIA N/A
- CUE N/A
- EPS
- MAIA N/A
- CUE N/A
- Revenue
- MAIA N/A
- CUE $7,991,000.00
- Revenue This Year
- MAIA N/A
- CUE N/A
- Revenue Next Year
- MAIA N/A
- CUE $23.84
- P/E Ratio
- MAIA N/A
- CUE N/A
- Revenue Growth
- MAIA N/A
- CUE 13.83
- 52 Week Low
- MAIA $1.40
- CUE $0.45
- 52 Week High
- MAIA $4.24
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- MAIA 41.47
- CUE 63.75
- Support Level
- MAIA $1.66
- CUE $0.65
- Resistance Level
- MAIA $1.95
- CUE $0.88
- Average True Range (ATR)
- MAIA 0.11
- CUE 0.07
- MACD
- MAIA -0.01
- CUE 0.02
- Stochastic Oscillator
- MAIA 7.82
- CUE 73.95
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.